Adam Feuerstein articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2015/04/19 13:22
2015/04/19 13:22
18m
For the treatment-experienced patients, the Keytruda response rate was 18% with a median duration of response of 10.4 months. Median progression-free survival was 3 months and median overall survival...
2015/04/19 13:22
2015/04/19 13:22
Latest videos
2015/04/14 13:22
2015/04/14 13:22
5d
NEW YORK (TheStreet) -- Aduro Biotech is expected to make its public markets debut Thursday with an initial public offering that will value the cancer immunotherapy developer at more than $1 billion....
2015/04/13 14:22
2015/04/13 14:22
5d
The original design of the MultiStem study used only the modified Rankin Scale to measure the stroke recovery primary endpoint. Last December, Athersys changed the assessment method for stroke...
2015/04/08 19:22
2015/04/08 19:22
10d
The key to Cytori's success, Hedrick said, is a medical device (Cytori Celution System) about the size of a washing machine. "We developed a cell therapy manufacturing setup," he said, "which is...
2015/04/08 14:22
2015/04/08 14:22
10d
BOSTON (TheStreet) -- Investors were treated to a hepatitis C data dump Wednesday ahead of a European liver disease meeting later in the month. Pretty much all the new data from ongoing hepatitis C...
2015/04/01 03:22
2015/04/01 03:22
18d
CAMBRIDGE, Mass. (TheStreet) -- Sarepta Therapeutics(SRPT - Get Report) on Tuesday announced the abrupt "resignation" of CEO Chris Garabedian. I'm using quotation marks around resignation because the...
2015/03/31 00:30
2015/03/31 00:30
19d
Today: The hot market for biotech mergers continues with the $1.1 billion purchase of Brisbane-based Hyperion Therapeutics, which wasn't even the biggest deal of the day. Also: Tesla Motors gains...
2015/03/30 23:38
2015/03/30 23:38
19d
Today: The hot market for biotech mergers continues with the $1.1 billion purchase of Brisbane-based Hyperion Therapeutics, which wasn't even the biggest deal of the day. Also: Tesla Motors gains...
2015/03/30 12:22
2015/03/30 12:22
20d
The deal values Auspex at $101 per share, a 42% premium to the Friday close of $70.91. Teva suggested last month that it would start to acquire smaller companies as a way to offset the expected...
2015/03/30 11:22
2015/03/30 11:22
20d
The all-cash deal values Hyperion at $46 a share, an 8% premium to Friday's close of $42.74. Hyperion had previously been the subject of takeout rumors, pushing its stock price higher ahead of...
2015/03/23 15:23
2015/03/23 15:23
26d
On Monday, Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped. The new VX-661 data in cystic-fibrosis patients aren't bad, per se,...
2015/03/20 17:23
2015/03/20 17:23
29d
Not everyone believes BIIB037 is destined to become a blockbuster Alzheimer's drug. Earlier today, I heard from a buyside source who is always skeptical. He writes: "How many times must provocative...
2015/03/20 15:19
2015/03/20 15:19
29d
Analysts are loving the latest news out of Biogen. Here's the key result, from the release: "Treatment with aducanumab produced a dose- and time-dependent reduction of amyloid plaque in the brain....
2015/03/20 12:29
2015/03/20 12:29
30d
In Alzheimer's patients who carry the AopeE4 gene, which puts them at higher risk for the disease, the rate of ARIA was 43% and 55% for the middle and high dose of BIIB037. This led to treatment...
2015/03/20 12:29
2015/03/20 12:29
30d
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in...
2015/03/19 12:22
2015/03/19 12:22
1m
CRANBURY, NJ (TheStreet) -- Amicus Therapeutics(FOLD - Get Report) will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors...
2015/04/19 13:22
2015/04/19 13:22
Latest from Twitter